BioNotebook: Agios, Kite raise cash on ASH buzz; plus 5 other public offerings
This article was originally published in Scrip
The 56th American Society of Hematology (ASH) Annual Meeting and Exposition from 6 to 9 December in San Francisco lifted the stock values of several companies with promising data for blood cancers, including Agios Pharmaceuticals and Kite Pharma, which are taking advantage of the buzz their lead programs generated at the ASH conference to raise a combined $408m in public offerings.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.